Changes in Beneficial Ownership · 4
Kiniksa Pharmaceuticals International, plc
KNSANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-09032026_080907.xml
Filing details
- Report period
- 2026-09-01
- Issuer
- Kiniksa Pharmaceuticals International, plc
- Issuer CIK
- 0001730430
- Trading symbol
- KNSA
Reporting owner 1
- Name
- Paolini John F.
- Reporting owner CIK
- 0001741533
- Relationship
- Officer
- Officer title
- CHIEF MEDICAL OFFICER
- Address
- C/O KINIKSA PHARMACEUTICALS INT'L, 105 PICCADILLY, SECOND FLOOR, LONDON, UNITED KINGDOM, X0, W1J 7NJ
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Class A Ordinary Share | 2026-09-01 | M · Form 4 | 2,497 | A | [F1] | 68,120 | D |
| Class A Ordinary Share | 2026-09-01 | M · Form 4 | 1,624 | A | [F1] | 69,744 | D |
| Class A Ordinary Share | 2026-09-01 | M · Form 4 | 1,750 | A | [F1] | 71,494 | D |
| Class A Ordinary Share | 2026-09-01 | M · Form 4 | 2,457 | A | [F1] | 73,951 | D |
| Class A Ordinary Share | 2026-09-01 | F · Form 4 | 4,029 | D | 79.28 | 69,922 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share Unit | [F1] | 2026-09-01 | A · Form 4 | 6,700 | A | 0 | [F2] | [F2] | Class A Ordinary Share | 6,700 | 6,700 | D |
| Share Option | 79.28 | 2026-09-01 | A · Form 4 | 26,750 | A | 0 | [F3] | 2036-08-31 | Class A Ordinary Share | 26,750 | 26,750 | D |
| Restricted Share Unit | [F1] | 2026-09-01 | M · Form 4 | 2,457 | D | 0 | [F4] | [F4] | Class A Ordinary Share | 2,457 | 7,371 | D |
| Restricted Share Unit | [F1] | 2026-09-01 | M · Form 4 | 1,750 | D | 0 | [F5] | [F2] | Class A Ordinary Share | 1,750 | 3,500 | D |
| Restricted Share Unit | [F1] | 2026-09-01 | M · Form 4 | 1,624 | D | 0 | [F6] | [F6] | Class A Ordinary Share | 1,624 | 1,624 | D |
| Restricted Share Unit | [F1] | 2026-09-01 | M · Form 4 | 2,497 | D | 0 | [F7] | [F7] | Class A Ordinary Share | 2,497 | 0 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
Footnotes
- F1
- Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9
- F2
- The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.↩ 1↩ 2↩ 3
- F3
- The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.↩ 1
- F4
- The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025.↩ 1↩ 2
- F5
- The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.↩ 1
Signature 1
- Signed
- /s/ Douglas Barry, Attorney-in-Fact
- Date
- 2026-09-03
Company context
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.